260 related articles for article (PubMed ID: 10492277)
1. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?
Diot E; Giraudeau B; Diot P; Degenne D; Ritz L; Guilmot JL; Lemarié E
Chest; 1999 Sep; 116(3):715-20. PubMed ID: 10492277
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
[TBL] [Abstract][Full Text] [Related]
4. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.
Volpinari S; La Corte R; Bighi S; Ravenna F; Prandini N; Lo Monaco A; Trotta F
Rheumatol Int; 2011 Sep; 31(9):1183-8. PubMed ID: 20352228
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
Hamaguchi Y
J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
[TBL] [Abstract][Full Text] [Related]
6. The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis.
Radić M; Martinović Kaliterna D; Ljutić D
Clin Exp Rheumatol; 2006; 24(4):407-12. PubMed ID: 16956431
[TBL] [Abstract][Full Text] [Related]
7. Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody.
Katsumi S; Kobayashi N; Yamamoto Y; Miyagawa S; Shirai T
Br J Dermatol; 2000 May; 142(5):1030-3. PubMed ID: 10809868
[TBL] [Abstract][Full Text] [Related]
8. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma.
Fava A; Cimbro R; Wigley FM; Liu QR; Rosen A; Boin F
Arthritis Res Ther; 2016 May; 18(1):99. PubMed ID: 27145754
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
Grassegger A; Pohla-Gubo G; Frauscher M; Hintner H
Wien Med Wochenschr; 2008; 158(1-2):19-28. PubMed ID: 18286246
[TBL] [Abstract][Full Text] [Related]
10. Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.
Motegi S; Toki S; Yamada K; Uchiyama A; Ishikawa O
J Dermatol; 2015 Feb; 42(2):189-92. PubMed ID: 25483258
[TBL] [Abstract][Full Text] [Related]
11. Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis.
Boonstra M; Bakker JA; Grummels A; Ninaber MK; Ajmone Marsan N; Wortel CM; Huizinga TWJ; Jordan S; Hoffman-Vold AM; Distler O; Toes REM; Scherer HU; de Vries-Bouwstra JK
Arthritis Rheumatol; 2020 Nov; 72(11):1897-1904. PubMed ID: 32840062
[TBL] [Abstract][Full Text] [Related]
12. Serological profile of patients with systemic sclerosis.
Wielosz E; Dryglewska M; Majdan M
Postepy Hig Med Dosw (Online); 2014 Aug; 68():987-91. PubMed ID: 25228505
[TBL] [Abstract][Full Text] [Related]
13. Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA.
Bankamp L; Preuß B; Pecher AC; Beucke N; Henes J; Klein R
Front Immunol; 2021; 12():786039. PubMed ID: 34956217
[TBL] [Abstract][Full Text] [Related]
14. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
Krzyszczak ME; Li Y; Ross SJ; Ceribelli A; Chan EK; Bubb MR; Sobel ES; Reeves WH; Satoh M
Clin Rheumatol; 2011 Oct; 30(10):1333-9. PubMed ID: 21523365
[TBL] [Abstract][Full Text] [Related]
15. Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?
Mahler M; Silverman ED; Schulte-Pelkum J; Fritzler MJ
Autoimmun Rev; 2010 Sep; 9(11):756-60. PubMed ID: 20601198
[TBL] [Abstract][Full Text] [Related]
16. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
[TBL] [Abstract][Full Text] [Related]
17. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.
Meyer OC; Fertig N; Lucas M; Somogyi N; Medsger TA
J Rheumatol; 2007 Jan; 34(1):104-9. PubMed ID: 17117486
[TBL] [Abstract][Full Text] [Related]
18. IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients.
García de la Peña-Lefebvre P; Chanseaud Y; Tamby MC; Reinbolt J; Batteux F; Allanore Y; Kahan A; Meyer O; Benveniste O; Boyer O; Guillevin L; Boissier MC; Mouthon L
Clin Immunol; 2004 Jun; 111(3):241-51. PubMed ID: 15183145
[TBL] [Abstract][Full Text] [Related]
19. Marker antibodies in scleroderma and polymyositis: clinical associations.
de Rooij DJ; Van de Putte LB; Habets WJ; Van Venrooij WJ
Clin Rheumatol; 1989 Jun; 8(2):231-7. PubMed ID: 2547546
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis.
Sato S; Hamaguchi Y; Hasegawa M; Takehara K
Rheumatology (Oxford); 2001 Oct; 40(10):1135-40. PubMed ID: 11600743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
